Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 19 of 19 entries
View as:

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT04469270 Org: User:
Start: 11/20/20 End: 07/31/24 Due: 07/31/25

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT04873232 Org: User:
Start: 05/17/21 End: 07/23/24 Due: 07/23/25

Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

Phase: N/A Priority: Normal
NCT ID: NCT01422772 Org: User:
Start: 01/31/07 End: 08/31/14 Due: 08/31/15

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

Phase: N/A Priority: Normal
NCT ID: NCT02563522 Org: User:
Start: 06/27/17 End: 09/24/19 Due: 09/24/20

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

Phase: N/A Priority: Normal
NCT ID: NCT00696124 Org: User:
Start: 04/03/07 End: 12/11/23 Due: 12/11/24

The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05552625 Org: User:
Start: 05/06/21 End: 02/24/22 Due: 02/24/23

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Phase: N/A Priority: Normal
NCT ID: NCT01064440 Org: User:
Start: 07/09/10 End: 11/17/23 Due: 11/17/24

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT01475786 Org: User:
Start: 08/31/12 End: 06/30/14 Due: 06/30/15

Gene Therapy for Painful Diabetic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT01002235 Org: User:
Start: 02/28/10 End: 04/30/12 Due: 04/30/13

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT02427464 Org: User:
Start: 04/30/16 End: 04/30/19 Due: 04/30/20

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05176093 Org: User:
Start: 11/14/21 End: 08/23/24 Due: 08/23/25

Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea

Phase: N/A Priority: Normal
NCT ID: NCT03404024 Org: User:
Start: 01/25/18 End: 08/20/19 Due: 08/20/20

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT04055090 Org: User:
Start: 02/04/19 End: 07/24/19 Due: 07/24/20

Gene Therapy for the Treatment of Chronic Stable Angina

Phase: N/A Priority: Normal
NCT ID: NCT01002495 Org: User:
Start: 03/31/15 End: 01/31/16 Due: 01/31/17

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT04632225 Org: User:
Start: 03/09/21 End: 07/15/24 Due: 07/15/25

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02039401 Org: User:
Start: 03/11/14 End: 03/06/24 Due: 03/06/25

Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis

Phase: N/A Priority: Normal
NCT ID: NCT01122485 Org: User:
Start: 12/31/06 End: 09/30/09 Due: 09/30/10

Gene Therapy for Chronic Granulomatous Disease in Korea

Phase: N/A Priority: Normal
NCT ID: NCT00778882 Org: User:
Start: 01/31/07 End: 10/31/10 Due: 10/31/11

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

Phase: N/A Priority: Normal
NCT ID: NCT05361031 Org: User:
Start: 09/21/20 End: 02/22/22 Due: 02/22/23